autologous tumor cell vaccine + sargramostim + activated white blood cells + aldesleukin

This drug is a **combination immunotherapy** composed of four distinct elements: - **Autologous tumor cell vaccine:** a personalized therapeutic vaccine created from the patient's own tumor cells, designed to stimulate an immune response against cancer cells by presenting a wide array of tumor-associated antigens. - **Sargramostim:** a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that acts as an immunostimulatory adjuvant, primarily by recruiting and activating antigen-presenting cells such as dendritic cells and macrophages, thereby enhancing immune response against tumor antigens[2][3][4][5]. - **Activated white blood cells:** typically refers to autologous lymphocytes or other immune cells that are isolated, activated (often ex vivo), and reinfused to boost anti-tumor immunity. This may include ex vivo stimulated T cells or other leukocyte subpopulations. - **Aldesleukin:** a recombinant human interleukin-2 (IL-2) that promotes T cell and natural killer (NK) cell proliferation and activation, further amplifying anti-tumor immune activity. The combination is intended for adoptive cellular immunotherapy and cancer vaccine approaches, leveraging both **antigen-specific** and **non-specific immune potentiation**. This approach is under clinical investigation for various cancers, aiming to induce robust, specific, and lasting anti-tumor immune effects.